Bayer reveals data behind asundexian's stroke win Bayer's oral Factor XIa inhibitor asundexian can reduce the risk of a secondary ischaemic stroke by 26%, according to the OCEANIC-STROKE trial

#Bayer #asundexian #stroke #oralFactorXIainhibitor #FactorXIainhibitor #ischaemicstroke #OCEANICSTROKEstudy #antiplatelettherapy #InternationalStrokeConference #phase3trial #secondarystrokeprevention #anticlottingtherapies #OCEANICSTROKE #acutecoronarysyndromes #preventionofstroke
zurl.co/Mhc1J